Comparative clinical and economic effectiveness of anti-vascular endothelial growth factor agents
Visual impairment is a common problem among Veterans and results in significant reduction in quality of life. Diseases commonly responsible for substantial losses in visual acuity include neovascular ("wet") age-related macular degeneration (AMD), diabetic macular edema (DME), and central...
| Main Author: | |
|---|---|
| Corporate Authors: | , , |
| Format: | eBook |
| Language: | English |
| Published: |
Washington, DC
Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service
2017, January 2017
|
| Series: | Evidence-based synthesis program
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Visual impairment is a common problem among Veterans and results in significant reduction in quality of life. Diseases commonly responsible for substantial losses in visual acuity include neovascular ("wet") age-related macular degeneration (AMD), diabetic macular edema (DME), and central or branch retinal vein occlusion (CRVO or BRVO). While the etiologies of these diseases are complex, all are driven at least in part by vascular endothelial growth factors (VEGFs). This has led to the development of several drugs called anti-VEGF agents designed to block these factors and thus limit their damage to the eye. The most commonly used anti-VEGF agents--aflibercept, bevacizumab, and ranibizumab--have been shown to slow and even reverse the vision loss typically seen in patients with AMD, DME, BRVO, and CRVO. The comparative effectiveness, harms, and costs of these drugs are unclear |
|---|---|
| Physical Description: | 1 PDF file (iv, 123 pages) illustrations |